Participated · Series C · Jan 2026

Beacon Therapeutics is a clinical-stage biotech focused on harnessing gene therapy for severe retinal disorders, notably X-linked retinitis pigmentosa (XLRP) and geographic atrophy. Its lead asset, laru-zova, is in pivotal trials and aims to become a best-in-class treatment for XLRP, with top-line data expected in the second half of 2026. The company estimates that about 14% of the 100,000 U.S. retinitis pigmentosa patients have the X-linked form, underscoring a significant unmet need. Newly raised capital will finance completion of laru-zova’s development and build the commercial infrastructure required for launch. Beacon is also advancing additional pipeline programs for geographic atrophy, an inherited cone-rod dystrophy, and another undisclosed ocular indication. Backed by a syndicate of leading life-science investors, the company remains pre-revenue and relies on venture funding to progress its portfolio.

Led · Series B · Sep 2025

Cyted Health offers a diagnostics platform built around EndoSign®, an FDA 510(k)-cleared device for minimally invasive collection of esophageal cells combined with advanced biomarker molecular testing. The company has completed over 35,000 tests across the UK’s National Health Service and has a portfolio of peer-reviewed publications demonstrating patient acceptability and clinical impact. Cyted was founded by experts at the University of Cambridge and is developing additional advanced diagnostic tests for pre-cancerous, cancerous, and inflammatory esophageal conditions. Management has expanded a Clinical Advisory Board of gastroenterology and oncology leaders to guide product development and clinical strategy. Near-term plans focus on consolidating commercial success in the UK, expanding the diagnostics portfolio, and accelerating commercial expansion in the US. Cyted was founded in 2020 by Professor Rebecca Fitzgerald OBE and Dr Marcel Gehrung and is based in Cambridge. Its diagnostic platform pairs a non-invasive test with data-driven biomarkers to enable earlier detection and risk stratification of cancers and inflammatory diseases, with an initial application in oesophageal cancer. The company's primary aim is to provide early-detection tests for oesophageal cancer to NHS patients in primary and community care settings. Cyted has delivered over 15,000 tests across more than 80 UK sites and has been rolling out community and primary-care testing since August 2022. It plans to use new funding to expand operations in existing markets, enter the US market, and further develop R&D programmes focused on gastrointestinal cancers and diseases. The recent financing and public-sector grants underline clinical traction and support for wider NHS deployment.

Led · Series C · Apr 2025

Glycomine is a clinical-stage biotech based in San Carlos, California, focused on developing transformative therapies for rare orphan diseases. Its lead candidate, GLM101, is a first-in-class mannose-1-phosphate replacement therapy designed to deliver mannose-1-phosphate into cells and bypass disease-causing PMM2 mutations to restore N-glycosylation. GLM101 has received Orphan Drug Designation in the U.S. and E.U., and Rare Pediatric Disease and Fast Track designations in the U.S. The company has enrolled more than 20 patients across Europe and the U.S. in an ongoing Phase 2 open-label study and has initiated dosing in pediatric patients. Data from the Phase 2 open-label study showed an average 11.9-point improvement on the ICARS among nine adult and adolescent patients over 24 weeks, providing clinical proof of concept for improvement in ataxia. Glycomine recently announced a $115 million Series C financing to support advancing GLM101 into a randomized, placebo-controlled Phase 2b safety and efficacy study later this year. Glycomine is a biotechnology company based in San Carlos, California, developing therapies for orphan diseases. Its lead candidate, GLM101, is a mannose-1-phosphate substrate replacement therapy designed to deliver mannose-1-phosphate intracellularly to bypass PMM2 enzyme deficiency and restore N-glycosylation. Preclinical studies have shown GLM101 can restore disrupted glycosylation pathways in PMM2-CDG. GLM101 has received Orphan Drug Designation in the U.S. and Europe and Rare Pediatric Disease Designation in the U.S. Glycomine plans to use the Series B proceeds to advance GLM101 into initial clinical trials and confirm clinical potential across PMM2-CDG genotypes. The company focuses on replacement therapies targeted to clinically relevant cellular compartments for rare metabolic and protein-misfolding disorders. Glycomine focuses on developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding. The company’s approach combines replacement therapies—substrates, enzymes, or proteins—with delivery vehicles made of bio-nanomaterials or ligands to target molecules to the cell interior of relevant organs. Glycomine intends to use the new capital to advance its substrate replacement therapy for PMM2‑CDG (CDG‑1a) into early-stage clinical studies. The company raised $33m in a Series B financing led by Novo Holdings A/S. In connection with the financing, Peter McWilliams, Ph.D., moved from acting CEO to full-time CEO. Kenneth Harrison, Ph.D., of Novo Ventures and Chris Starr, Ph.D., joined the company’s board. Glycomine is a San Francisco, CA–based biotechnology company developing a new generation of replacement therapies for rare monogenic disorders of metabolism and protein misfolding. Its approach combines replacement therapies—substrates, enzymes, or proteins—with intracellular delivery vehicles consisting of bio‑nanomaterials or targeting ligands to deliver molecules into clinically relevant organs. The company is led by CEO Agnes Rafalko, PhD, with Christopher Starr, PhD serving as Executive Chairman. Glycomine raised $12m in a Series A financing to advance its pipeline. The company intends to use the funds to complete IND‑enabling preclinical studies and initiate clinical studies of a substrate replacement therapy in patients with Congenital Disorder of Glycosylation Type Ia (CDG‑Ia). Proceeds will also be used to accelerate discovery efforts toward an enzyme replacement therapy for N‑glycanase deficiency (Ngly1).

Led · Series A · Jan 2025

Relief Cardiovascular is a privately held medical device company and an inQB8 Medical Technologies portfolio company focused on improving outcomes for patients with heart failure. Its flagship product, the Relief System, is a transcatheter smart implant that uses a "puller" mechanism and integrated sensors to autonomously capture renal vein pressures and multiparametric data. The system is designed to both monitor renal pressures and therapeutically modulate them, providing physicians actionable data to optimize fluid management—including for diuretic-resistant heart failure. The company plans to use new funding to advance product development and to initiate a first-in-human feasibility study to evaluate the safety and efficacy of the Relief System. Relief Cardiovascular has closed a $12M Series A to support these activities and is advancing toward human clinical studies. The company was founded and incubated within inQB8 Medical Technologies and is based in Irvine, Calif.

Participated · Series A · Oct 2024

Epitopea develops accessible, off-the-shelf RNA-based immunotherapies that target a new class of broadly shared tumor-specific antigens termed Cryptigen™ TSAs. The company discovers Cryptigen™ TSAs using its proprietary CryptoMap™ platform, which leverages immunopeptidomics, genomics and a bioinformatics pipeline to identify aberrantly expressed tumour-specific antigens hidden in cancer’s ‘junk’ DNA. Its Cryptigen™ antigens were first discovered through research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at the Université de Montréal. Epitopea intends to use the new funding to support strategic development and the clinical entry of its lead Cryptigen immunotherapeutics. Led by CEO Dr. Alan C. Rigby, the company operates sister entities in Cambridge, UK and Montreal, Canada. To date, Epitopea has raised more than USD $45M in financing. Epitopea, based in Cambridge, UK and Montreal, Canada, develops accessible off-the-shelf RNA-based immunotherapies for hard-to-treat cancers. The company focuses on a new class of untapped antigens—CryptigenTM TSAs—identified by its proprietary CryptoMapTM platform, which leverages immunopeptidomics, genomics, and a bioinformatics pipeline. CryptoMap discovers aberrantly-expressed tumor-specific antigens (aeTSAs) hidden within cancer’s 'junk' DNA; these hidden CryptigenTM TSAs were first discovered through research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at the Université de Montréal. Epitopea is developing both therapeutic vaccines and T cell receptor-based therapies targeting antigens differentially presented by stromal cells. Led by CEO Dr. Alan C. Rigby, the company recently received a £500K non-dilutive grant from Innovate UK’s Cancer Therapeutics programme to support this research. The funding is intended to advance vaccines and TCR-based approaches against antigens that are broadly shared across multiple patients with the same tumor type. Epitopea is a Cambridge, UK and Montreal, Canada‑based biotechnology company developing cancer immunotherapies that target a newly described class of tumour‑specific antigens called Cryptigen™ TSAs. The company discovers these conserved, aberrantly expressed antigens using a proprietary approach combining immunopetidomics, mass spectrometry, genomics, and bioinformatics. Epitopea plans to translate these discoveries into novel cancer immunotherapeutics, including therapeutic vaccines, cell therapies, and TCR‑based biologics. The hidden Cryptigen™ TSAs were identified in research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. Led by CEO Dr. Jon Moore (also an Operating Partner at Advent Life Sciences), the company intends to use new funding to build its executive team and advance further research and translational programs. Financially, Epitopea completed a seed financing to support these R&D and team‑building activities.